文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT预测膀胱癌新辅助化疗肿瘤反应的系统评价与Meta分析

Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
PubMed 文献 · Clin Nucl Med · 2023-03-26

该系统评价与Meta分析检索PubMed、Cochrane和Embase数据库至2022年11月30日,纳入5项研究(12个结果),评估18F-FDG PET/CT预测膀胱癌患者新辅助化疗肿瘤反应的诊断效能,汇总灵敏度0.84、特异度0.75,作者认为其表现出良好的诊断性能。

要点

  • 5项研究(12个结果)汇总,18F-FDG PET/CT预测肿瘤反应的灵敏度0.84、特异度0.75。
  • 预测病理完全缓解的汇总灵敏度0.68、特异度0.77。
  • 预测临床缓解与无缓解的汇总灵敏度0.94、特异度0.73。

核心结论

  • 18F-FDG PET/CT在预测膀胱癌患者新辅助化疗肿瘤反应方面表现出良好的诊断性能。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane数据库和Embase数据库自建库至2022年11月30日的文献。
  • 纳入5项研究(12个结果),基于患者层面和病灶层面提取数据计算汇总灵敏度、特异度及95%CI。

主要发现

  • 18F-FDG PET/CT预测肿瘤反应的汇总灵敏度为0.84(95%CI 0.72-0.91),汇总特异度为0.75(95%CI 0.59-0.86)。
  • 汇总阳性似然比为3.3(95%CI 2.0-5.6),汇总阴性似然比为0.22(95%CI 0.12-0.38),汇总诊断比值比为15(95%CI 7-36)。
  • 预测病理完全缓解的汇总灵敏度为0.68(95%CI 0.56-0.78),汇总特异度为0.77(95%CI 0.60-0.88)。
  • 预测临床缓解与无缓解的汇总灵敏度为0.94(95%CI 0.85-0.98),汇总特异度为0.73(95%CI 0.42-0.91)。

关键数值与推荐

  • 18F-FDG PET/CT预测肿瘤反应:汇总灵敏度0.84(95%CI 0.72-0.91),汇总特异度0.75(95%CI 0.59-0.86)。
  • 预测病理完全缓解:汇总灵敏度0.68(95%CI 0.56-0.78),汇总特异度0.77(95%CI 0.60-0.88)。
  • 预测临床缓解与无缓解:汇总灵敏度0.94(95%CI 0.85-0.98),汇总特异度0.73(95%CI 0.42-0.91)。
  • 汇总阳性似然比3.3(95%CI 2.0-5.6),汇总阴性似然比0.22(95%CI 0.12-0.38),汇总诊断比值比15(95%CI 7-36)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of the current study was to evaluate the diagnostic accuracies of 18 F-FDG PET/CT for prediction of tumor response to neoadjuvant chemotherapy in bladder cancer (BC) patients through a systematic review and meta-analysis. PATIENTS AND METHODS: The PubMed, Cochrane database, and Embase database were searched from inception through November 30, 2022 for studies evaluating diagnostic performance of 18 F-FDG PET/CT for prediction of tumor response to neoadjuvant chemotherapy in BC patients. Based on data extracted from patient-based and lesion-based analysis, we calculated the pooled sensitivity and specificity with the 95% confidence intervals (CIs). Also, we calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. RESULTS: Across 5 studies (12 results), the pooled sensitivity of 18 F-FDG PET/CT was 0.84 (95% CI, 0.72-0.91), and the pooled specificity was 0.75 (95% CI, 0.59-0.86). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 3.3 (95% CI, 2.0-5.6) and negative likelihood ratio (LR-) of 0.22 (95% CI, 0.12-0.38). The pooled diagnostic odds ratio was 15 (95% CI, 7-36). The pooled sensitivity of 18 F-FDG PET/CT for prediction of pathologic complete response was 0.68 (95% CI, 0.56-0.78), and the pooled specificity was 0.77 (95% CI, 0.60-0.88). The pooled sensitivity of 18 F-FDG PET/CT for prediction of clinical response and nonresponse was 0.94 (95% CI, 0.85-0.98), and a pooled specificity was 0.73 (95% CI, 0.42-0.91). CONCLUSIONS: 18 F-FDG PET/CT showed a good diagnostic performance for prediction of tumor response to neoadjuvant chemotherapy in BC patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ko WS, Kim SJ. Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer. Clin Nucl Med. 2023. PMID: 36976654. doi:10.1097/RLU.0000000000004639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。